Aarey Drugs & Pharmaceuticals Ltd
- Market cap
- ₹ 296 Cr.
- P/E
- 82.9x
- P/B
- 2.09x
- 52-week range
- 50.31 – 114.8
- ROE
- 3%
- ROCE
- 6%
- Dividend yield
- 0%
- Debt / equity
- 0.33
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Aarey Drugs and Pharmaceuticals Limited is an India-based company, which is engaged in the manufacturing and trading of drugs and pharmaceuticals. The Company is in active pharmaceutical ingredients (API)/bulk drug manufacturing and offers a range of products for various industrial applications. Its products include N-Methyl Urea, Mefenamic acid, Doxofylline, Lumefantrine, Nimesulide, Albendazole, Carbamazepine and Oxcarbazepine. The Company's chemical and solvents include Aeromatics Chemical, Chemical acid, Chlor Alkali, Industrial Alchols, Industrial Ketones, Glycols and Glycol Ethers, Fiber Intermediates, Industrial Amines, Acetates and Esters, Industrial Oleochemicals, Industrial Intermediates, Chlorinated Solvents, Industrial Olefines, Industrial Phosphates, Industrial Fertilizers, Industrial Monomers and Industrial Chemicals. Its chemical acid products include Acetic acid, Citric acid, Formic acid and Hydrochloric acid.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Aarey Drugs & Pharmaceuticals Ltd against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)82.9 against a typical 34.3: pricier than most peers (1st = cheapest).184th of 220
- Sales growth−56.3% against a typical +15.6% from a year earlier.188th of 197
- Profit growth−25.5% against a typical +18.9% from a year earlier.119th of 160
- Share price, 3 months+45% against a typical −0.5%.14th of 200
- Size₹ 295.6 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).109th of 199
Latest announcements
Exchange filings and their impact on the company.
- Aarey allotted 11.5L shares on warrant conversion, raising Rs 5.5 cr with ~3.7% dilution.
Aarey Drugs board on 30 Sep 2026 allotted 11.5 lakh equity shares on conversion of warrants at Rs 63.80 per share, receiving Rs 47.85 per warrant totalling Rs 5.5 crore. This follows conversion of 23.7 lakh warrants on 6 Aug 2026, leaving 14.8 lakh warrants of the 50 lakh issued in May 2025 outstanding. The cash strengthens the balance sheet and working capital funding with modest ~3.7% dilution, including participation by a promoter and public investors.
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Look closer
Rated BB+ by Acuite- Acuite lowered its rating on 27 May 2026.
- The company stopped sharing information with ICRA.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| ICRA | [ICRA]B+ ISSUER NOT COOPERATING | Stable | 27 Oct 2026 |
| Acuite | ACUITE BB+ | — | 27 May 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 27 Oct 2026 | Reaffirmed | [ICRA]B+ ISSUER NOT COOPERATING | — | ICRA | ₹ 45 Cr. | |
| 27 May 2026 | ▼ Downgrade | ACUITE BB+ | — | Acuite | ₹ 65.94 Cr. | |
| 26 Aug 2025 | Rating action | [ICRA]B+ ISSUER NOT COOPERATING | — | ICRA | ₹ 45 Cr. |
Fund raises
QIPs, preferential issues, warrants and rights issues, one row per filing, newest first. Open a row for details. All fund raise updates
| Stage | Details | |||||
|---|---|---|---|---|---|---|
| 7 Oct 2026 | Warrant conversion | Allotted | ₹ 5.5 Cr. | ₹ 63.8 | +71.79% |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 14 Aug 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 30 May 2026 | Financial Results | AAREYDRUGS : 30-May-2026 : The Company has informed the Exchange that a Board meeting to be held on May 29, 2026 has been re-scheduled. Further, the Company has informed the Exchange that the meeting of the Board of Directors of the Company will be held on May 30, 2026, To consider and approve the financial results for the period ended March 31, 2026 |
| 29 May 2026 | Financial Results | To consider and approve the financial results for the period ended March 31, 2026 |
| 11 Feb 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 13 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 13 Aug 2025 | Financial Results | To consider and approve the Unaudited financial results for the period ended Jun 30, 2025 |
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 58 | 76 | 210 | 127 | 105 | 134 | 108 | 102 | 84 | 96 | 189 | 45 |
| Expenses | 56 | 74 | 212 | 126 | 101 | 132 | 112 | 101 | 82 | 98 | 185 | 43 |
| Operating Profit | 2 | 3 | −1 | 1 | 4 | 2 | −4 | 2 | 3 | −2 | 4 | 1 |
| OPM % | 3.2% | 3.5% | −0.7% | 0.9% | 3.5% | 1.6% | −3.9% | 1.7% | 3.1% | −1.6% | 2.3% | 3% |
| Other Income | 1 | 0 | 5 | 2 | 0 | 1 | 8 | 2 | 1 | 4 | −0 | 2 |
| Interest | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 2 |
| Depreciation | 1 | 1 | 1 | 0 | 2 | 1 | 0 | 0 | 1 | 1 | 1 | 1 |
| Profit before tax | 1 | 1 | 2 | 1 | 2 | 1 | 2 | 2 | 1 | 1 | 1 | 1 |
| Tax % | −22% | 30.1% | −0.5% | 6.8% | 8.6% | 48.6% | 71.6% | 20.8% | 31.1% | 38% | −21.9% | −98.1% |
| Net Profit | 1 | 1 | 2 | 1 | 2 | 1 | 0 | 1 | 1 | 1 | 2 | 1 |
| EPS in Rs | 0.48 | 0.4 | 0.77 | 0.44 | 0.57 | 0.25 | 0.17 | 0.48 | 0.36 | 0.2 | 0.55 | 0.36 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 7%
- 5 Years
- 6%
- 3 Years
- 4%
- TTM
- −8%
- 10 Years
- 12%
- 5 Years
- −9%
- 3 Years
- 2%
- TTM
- 0%
- 10 Years
- 7%
- 5 Years
- 17%
- 3 Years
- 19%
- TTM
- —
- 10 Years
- 5%
- 5 Years
- 4%
- 3 Years
- 3%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Aarey Drugs & Pharmaceuticals Ltd | ₹ 109.60 | ₹ 296 Cr. | 82.9x | 2.1x | 3% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Mihir R. Ghatalia
- Chairman of the Board, Managing Director
- Mira Mihir Ghatalia
- Chief Financial Officer
- Kailash Chand Jethlia
- Compliance Officer, Company Secretary
Prices are delayed and for information only. Nothing on this page is investment advice.